Earnings summaries and quarterly performance for MUSTANG BIO.
Research analysts covering MUSTANG BIO.
Recent press releases and 8-K filings for MBIO.
Mustang Bio, Inc. Stockholders Approve Share Plan Amendments and Terminates CD20 License
MBIO
Proxy Vote Outcomes
New Projects/Investments
- Mustang Bio, Inc. held its 2025 Annual Meeting on December 22, 2025, where stockholders approved amendments to the 2019 Employee Stock Purchase Plan (ESPP) and the 2016 Incentive Plan (EIP).
- The ESPP was amended to increase the number of shares issuable by 250,000 shares and the individual Purchase Right to 10,000 shares.
- The EIP was amended to increase the aggregate number of shares reserved for issuance by 2,500,000 shares.
- On December 17, 2025, the company terminated its CD20 License Agreement with Fred Hutchinson Cancer Center, agreeing to pay $730,000 to extinguish approximately $1.4 million in outstanding payables. Fred Hutch will also pay Mustang Bio at least 10% of future third-party licensing consideration for the CD20 patents.
Dec 23, 2025, 9:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more